logo
Plus   Neg
Share
Email

Lilly To Buy AurKa Pharma

Eli Lilly and Co. (LLY) said that it agreed to acquire AurKa Pharma, Inc., a company established by TVM Capital Life Science to develop oncology compound AK-01, an Aurora kinase A inhibitor that was originally discovered at Lilly. The compound is a potential first-in-class asset that AurKa Pharma is studying in Phase 1 clinical trials in multiple types of solid tumors.

As per the terms of the agreement, Lilly will acquire all shares of AurKa Pharma. In return, AurKa Pharma shareholders will receive an upfront payment of $110 million. AurKa Pharma shareholders are also eligible to receive up to $465 million in regulatory and sales milestones should AK-01 gain approval in the U.S. and other markets, and achieve certain sales levels.

Lilly said that the transaction will be reflected in its reported results and financial guidance according to Generally Accepted Accounting Principles (GAAP), and is subject to customary closing conditions. There will be no change to Lilly's 2018 non-GAAP earnings per share guidance as a result of this transaction.

For comments and feedback contact: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
After failing to sustain an initial upward move, stocks showed a lack of direction over the course of the trading session on Tuesday. The major averages pulled back off their early highs and spent the rest of the day bouncing back and forth across the unchanged line. Under pressure from President Donald Trump, Senate Majority Leader Mitch McConnell, R-Ken., announced Tuesday the Senate will hold a vote on a criminal justice reform bill before the end of the year. In a tense public exchange with Democratic leaders on Tuesday, President Donald Trump took ownership of a potential shutdown of key government agencies over the issue of funding of his controversial border wall. "If we don't get what we want, one way or the other," Trump said, "I will shut down the government, absolutely."
Follow RTT